Joint UCD and Newcastle University spin-out emerges from €50m pan-European Mobilise-D project
Michael McMahon, Enoda
Healthtech start-up Enoda has launched a novel platform to deliver real-world mobility data to global pharmaceutical, medtech and clinical research partners.
The data will enable them to gain unprecedented insight into how their therapies impact patient mobility in everyday life.
For patients with conditions like Parkinson’s, MS, and COPD, mobility is a vital aspect of health. However, drug development has historically been slowed by the lack of measurement tools that can assess mobility accurately in real-world settings.
“The launch of Enoda as an independent spin-out from UCD and Newcastle University marks a pivotal moment for clinical research and will realise the many benefits real-world mobility data can bring to drug development,” Michael McMahon, CEO of Enoda, said.
He added: “By transforming the groundbreaking €50 million Mobilise-D research into a fully realised, customer-ready Electronic Data Capture platform, we are giving pharma and medtech companies the tools they need to capture accurate and meaningful mobility data.”
Enoda’s novel platform, designed to meet the rigorous demands of modern clinical trials is addressing this critical gap, empowering researchers and pharmaceutical companies with clinically meaningful, high-fidelity data to enhance patient insight and therapeutic development.
Enoda recently spun out of University College Dublin (UCD) and Newcastle University jointly with the support of NovaUCD and Newcastle Innovations and is an Enterprise Ireland High-Potential Start-Up (HPSU) company.
The company has emerged from research led by Prof Lynn Rochester, Translational and Clinical Research Institute and colleagues at Newcastle University and by Prof Brian Caulfield, UCD School of Public Health, Physiotherapy and Sports Science and colleagues at UCD, as part of Mobilise-D.
Mobilise-D, a five-year €50 million pan-European project which concluded in 2024, was funded by the Innovative Medicines Initiative (IMI) with the focus of transforming how mobility loss is measured in people with chronic conditions, such as Parkinson’s, MS, and COPD.
The technology has been robustly validated in a technical validation study with c.100 participants across 6 cohorts and a clinical validation study with 2,366 participants across four disease cohorts, as part of Mobilise-D.
Enoda is based at the Cobh Enterprise Centre in Co. Cork.
Patryk Goron
Source link
